Figure 19 is titled “Change in CAPS for anticonvulsants compared with placebo.” The figure displays a forest plot reporting the standardized mean difference in CAPS stratified by divalproex compared with placebo, tiagabine compared with placebo, and topiramate compared with placebo. This figure is described further in the “PTSD symptoms” section as follows: “Five of the included studies reported CAPS-assessed PTSD symptom changes between groups. Among the three topiramate trials, only one found significant differences across groups, although all effect sizes consistently favored topiramate (Figure 19; low SOE). One trial testing divalproex and another testing tiagabine provided insufficient evidence of efficacy for PTSD symptoms due to unknown consistency and imprecise findings.” Overall standardized mean difference, −0.54; 95% CI −1.17 to 0.10.

Figure 19Change in CAPS for anticonvulsants compared with placebo

CAPS = Clinician-Administered PTSD Scale; CI = confidence interval; SMD = standardized mean difference; WMD = weighted mean difference.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.